Vertex outlines 8% to 9% revenue growth for 2026 as non-CF products gain momentum
View original at seekingalpha.comVertex outlines 8% to 9% revenue growth for 2026 as non-CF products gain momentum Earnings Call Insights: Vertex Pharmaceuticals Incorporated (VRTX) Q4 2025 MANAGEMENT VIEW * CEO Reshma Kewalramani highlighted "excellent progress across the business, disciplined commercial execution in CF and the new product launches,…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Vertex plans to double the size of its field force in quarter 2 of 2026
80% confidencePovetacicept is an engineered fusion protein with better potency, better binding affinity, better pharmacokinetics, and better tissue distribution
80% confidenceThe 36-week proteinuria data in RUBY-3 showed a 56% reduction in proteinuria
80% confidenceCombined non-GAAP operating expenses expected to be in the range of $5.65 billion to $5.75 billion for 2026
80% confidenceFull year 2025 total revenue was $12 billion, an increase of 9% versus 2024
80% confidenceIn RUBY-3 study, there are no serious adverse events related to hypogammaglobulinemia and none of infection, regardless of IgG level
80% confidenceIn 2026, Vertex expects to more than triple the number of JOURNAVX prescriptions compared to approximately 550,000 written in 2025
80% confidenceThe renal pipeline is a key engine for Vertex's next decade of growth
80% confidenceVertex has had 74 payer engagements covering over 210 million lives as of the earnings call
80% confidenceVertex achieved excellent progress across the business, disciplined commercial execution in CF and the new product launches, meaningful pipeline progress and robust financial performance
80% confidence2026 focus will be on increasing the number of patients served and further diversifying revenue base
80% confidenceALYFTREK has once-daily dosing, regulatory approval in additional mutations and the best CFTR protein function restoration in Vertex's CF portfolio
80% confidenceQ4 2025 non-GAAP net income was $1.3 billion, up 24% year-over-year, delivering $5.03 of earnings per share, up 26% versus the prior year
80% confidenceWhen patients are not at the very tail end close to dialysis, GFR baseline should not have great impact on proteinuria
80% confidenceFull year 2026 total company revenue expected to be in the range of $12.95 billion to $13.1 billion, representing 8% to 9% growth
80% confidence2026 outlook anticipates $500 million or greater revenue contribution from non-CF products
80% confidenceVertex ended 2025 with $12.3 billion in cash, cash equivalents and marketable securities
80% confidenceVertex feels good about payer engagements and their future trajectory
80% confidenceQ4 2025 total revenue reached $3.2 billion, a 10% increase compared to Q4 2024
80% confidenceNon-GAAP effective tax rate projected to be in the range of 19.5% to 20.5% for 2026
80% confidence